Top Tech Companies (2,070)
Don't see your company?
Create a company profile
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com.
Bioscan develops instrumentation for the detection, synthesis, and imaging of radio-labeled compounds used in several fields.
Hera Health Solutions is a pharmaceutical company specializing in the development and commercialization of long term treatments.
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.
Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Precision Biologics is a Biotechnology company located in 5910 N Central Expy, Dallas, Texas, United States.
Scioto is a developer of Activated Bacterial Therapeutics (ABT) platform intended to deliver live bacteria to the gut.
RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.
First Wave Bio develops medical solutions to address the lack of effective and safe treatments for Inflammatory Bowel Disease (IBD).
Grolltex for 'graphene-rolling-technologies' is an early stage company with breakthrough technology in the field of CVD graphene production
Pillar Biosciences was founded in 2014, on the principle that in order for personalized medicine to be realized, clinical Next Generation Sequencing (NGS) workflows need to be affordable, rapid, robust, and flexible. We’re focused on productive solutions that enable streamlined workflows, so that labs can generate dependable results with less inputs, less labor, and less time. Our team makes precision medicine practical through simple, efficient sequence enrichment technology and straightforward bioinformatics tools broadly available to molecular labs worldwide.
NeuroLaunch is the world’s first accelerator program for neuroscience startups. We apply the methodology of lean early-stage company acceleration, which has risen to global prominence as a model for high-tech startups, to neuroscience.
Nova Analytic Labs is a unique comprehensive laboratory specializing in quality science, medicine and research in the Cannabis Community.
MultiVir is a clinical-stage gene therapy company
Pattern Ag is developing a recommendation and product discovery platform centered around a deep understanding of soil. We are leveraging advances in genomics, robotics, and high-resolution agronomic data to build this knowledge, in service of improving farm profitability
We are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. Our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. With a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. It is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer
PHusis Therapeutics is developing novel targeted small molecule therapeutics
Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.
Exegenesis Bio is a clinical-stage global cell and gene therapy company that operates in Philadelphia, Boston, China, and Singapore. Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The company is advancing an early to clinical-stage gene therapy pipeline with three initial focused therapeutic areas: CNS, ophthalmology, and Liver. The company’s vision is to develop and increase access to gene and cell therapies for patients around the world! Founded in 2019 with strong financial backing, Exegenesis Bio has developed a rich pipeline of early to clinical stage programs in eye, CNS and liver-directed genetic diseases. The company is building fully integrated, research, development and manufacturing capabilities to support its programs at commercial scale. Exegenesis Bio has recruited a globally experienced management team with extensive experience in building and scaling biotechnology and gene therapy companies. The company has raised over $120 M since beginning operations in 2019 and is now expanding operations to Philadelphia, Boston and Singapore. Exegenesis Bio expects to dose the first patient with its next generation AAV gene therapy for Type 1 Spinal Muscular Atrophy (SMA) this year. The company plans to file two Global INDs in 2022. Website: https://www.exegenesisbio.com/ Contacts: Company Information: [email protected] Business Development: [email protected] Careers: [email protected]
Monoceros Biosystems is a biotechnology company that offers personalized applications of bioinformatics in drug discovery.
